Search Browse Earnings

Apogee Therapeutics, Inc.

Nasdaq:APGE

Biological Products, (No Diagnostic Substances)·WALTHAM, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CEO

Henderson Michael Thomas

CFO

Henderson Jane

Revenue

—

Adj. EBITDA

-$92.8M

FY 2025

Net Income

-$84.0M

FY 2025

EPS (Diluted)

-$3.36

FY 2025

Stock Price

$74.68

-0.9%

2026-03-11

52W Range

$26.20 – $84.56

P/E Ratio

-22.2x

Market Cap

—

Cash

$118.3M

FY 2025

Total Debt

—

Net Cash

$118.3M

Enterprise Value

—

Debt / EBITDA

1.3x

FY 2025

EV / EBITDA

—

Employees

—